Raltegravir: First in class HIV integrase inhibitor

Zelalem Temesgen, Dawd S. Siraj

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.

Original languageEnglish (US)
Pages (from-to)493-500
Number of pages8
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number2
StatePublished - 2008

Fingerprint

Integrase Inhibitors
Viruses
Anti-Retroviral Agents
HIV
drug
HIV-1
event
evidence
Phase III Clinical Trials
Virus Diseases
United States Food and Drug Administration
Creatine Kinase
Transaminases
Liver
Nausea
Headache
Diarrhea
Therapeutics
Pharmaceutical Preparations
Raltegravir Potassium

Keywords

  • Antiretroviral agents
  • HIV
  • Integrase inhibitors
  • Ralteravir

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Raltegravir : First in class HIV integrase inhibitor. / Temesgen, Zelalem; Siraj, Dawd S.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 2, 2008, p. 493-500.

Research output: Contribution to journalArticle

@article{37e465d8455745cc8390bef07f68f759,
title = "Raltegravir: First in class HIV integrase inhibitor",
abstract = "On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-na{\"i}ve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.",
keywords = "Antiretroviral agents, HIV, Integrase inhibitors, Ralteravir",
author = "Zelalem Temesgen and Siraj, {Dawd S.}",
year = "2008",
language = "English (US)",
volume = "4",
pages = "493--500",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Raltegravir

T2 - First in class HIV integrase inhibitor

AU - Temesgen, Zelalem

AU - Siraj, Dawd S.

PY - 2008

Y1 - 2008

N2 - On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.

AB - On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.

KW - Antiretroviral agents

KW - HIV

KW - Integrase inhibitors

KW - Ralteravir

UR - http://www.scopus.com/inward/record.url?scp=44049098603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44049098603&partnerID=8YFLogxK

M3 - Article

C2 - 18728839

AN - SCOPUS:44049098603

VL - 4

SP - 493

EP - 500

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 2

ER -